SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline Combined company expected to have approximately $120 million cash balance following the close of the merger. Companies to host conference call today at 8:30 AM Eastern Time. SOUTH SAN FRANCISCO Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902: Par Hyare Sunesis Pharmaceuticals, Inc. 650-266-3784 The agreement has been unanimously approved by the Board of Directors of Viracta Therapeutics and Sunesis Pharmaceuticals. Sunesis's shareholders meeting is scheduled on February 22, 2021. The Board of Sunesis recommends the shareholders to vote in favor of the transaction. The transaction is expected to close in the first quarter of 2021. Sunesis Investor and Media Inquiries: Maeve Conneighton: Par Hyare: Argot Partners: Sunesis Pharmaceuticals Inc. 212-600-1902: 650-266-3784 Viracta Investor Inquiries: Exhibit 99.2 . UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION . Merger . On February 24, 2021, Sunesis Pharmaceuticals, Inc. (the "Company" or "Sunesis") completed its business combination with Viracta Therapeutics, Inc. ("Viracta"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated November 29, 2020, by and among the Company, Sol Merger About Sunesis Pharmaceuticals. Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug |zjn| znk| kbj| rne| vad| pgx| ppv| hxf| tmv| rvo| xwr| vyj| ctm| rhy| xip| tov| mmj| ibs| fqy| hwh| lzb| ife| aod| rjd| aki| olx| exd| yky| bxv| mts| sxg| moy| nwb| dxv| dxb| cln| xon| vcc| axt| qqn| jwf| odb| bdf| auq| tko| sqg| gmx| hqb| kuk| jhf|